Global Pembrolizumab Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Pembrolizumab Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Pembrolizumab is a therapeutic antibody that binds and blocks PD-1 located on lymphocytes. This receptor is usually responsible for preventing the immune system from attacking the body's own tissues. Keytruda® is the trade drug name of Pembrolizumab.

Since 2019, Pembrolizumab has been used by intravenous infusion to treat melanoma, metastatic non-small cell lung cancer (NSCLC) that is inoperable or metastatic in some cases, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin after platinumbased chemotherapy, it can be used as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), and it can treat refractory classic Hodgkin lymphoma (CHL) in adults and children and recurrent locally advanced or metastatic esophageal squamous cell carcinoma.

Market Overview:

The latest research study on the global Pembrolizumab market finds that the global Pembrolizumab market reached a value of USD 18644.34 million in 2022. It’s expected that the market will achieve USD 25884.98 million by 2028, exhibiting a CAGR of 5.62% during the forecast period.

Influence of COVID-19 Outbreak on Pembrolizumab Industry Development

The society has been significantly suffered from the outbreak of CIVD-19. Many industries are expected to be in trouble due to the decrease of demand and the shut down of factories. However, because Pembrolizumab is a medicine that can cure or comfort patients with cancer, the impact on the demand side will have some effects while the supply chain is seriously affected.

Pembrolizumab is a necessity to patients who desperately rely on it to continue their life. Although the likelihood of world economy stepping in recession is high, and those people may get into severe financial trouble, the government and charity will help them out and overall demand is not as seriously affected as the supply side.

The supply chain is an important part during sales. Without production, the entire sales process will collapse. However, the outbreak of COVID-19 forced government to declare an emergency and regulates enterprise to shut down the business and stay at home. General research, production and sales activity are temporarily stopped. According to Merck, they help only eligible patients living in the USA figure out what to do during this difficult time. Therefore, considering the effects of both demand and supply, we expect the market will still grow but not as quick as last year.

Strength

Increasing downstream demand.
Continuous improvement of production process.

Weakness

Only one company is produing the medicine and less than 20 authorzied distributors.
may limit the circulation of the drug.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Merck & Co., Inc. is one of the major players operating in the Pembrolizumab market, holding a share of 100% in 2020.

Merck Pharmaceuticals, founded in 1891, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck provides health solutions through its prescription drugs, vaccines, biotherapy, animal health and consumer health products. The company has operations in the fields of pharmaceuticals, animal health and consumer health.

Segmentation Overview:

Among different product types, 100mg Injection segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the NSCLC segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Pembrolizumab market covered in Chapter 3:

Merck & Co., Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Pembrolizumab market from 2018 to 2029 is primarily split into:

50mg Injection
100mg Injection

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Pembrolizumab market from 2018 to 2029 covers:

Melanoma
Non-Small Cell Lung Cancer NSCLC
Head and Neck Squamous Cell Carcinoma HNSCC
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)